Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 6;10(7):e005025. doi: 10.1136/jitc-2022-005025

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Myeloid markers predict survival in a histology-dependent manner. (A) High (above the median) levels of CD68 associated with survival significantly in Cohort 1 (p=0.001) but not significantly in Cohort 2 (p=0.065). High levels of HLA-DR associated significantly with survival in Cohort 2 (p=0.031), but not in Cohort 1. (B) High levels of CD68 and HLA-DR associated with improved survival in both large cohorts among adenocarcinomas (CD68: p=0.036, p=0.0002; HLA-DR: p=0.014, p=0.038). Among squamous cell carcinomas, high levels of CD68 and HLA-DR did not significantly associate with improved survival, and in fact trended in the opposite direction. ADC, adenocarcinoma; SCC, squamous cell carcinoma.